The food enzyme is a b-galactosidase (b-D-galactoside galactohydrolase; EC 3.2.1.23) produced with the genetically modified Escherichia coli strain NCIMB 30325 by Clasado Ingredients Ltd. The b-galactosidase encoding gene is introduced into the recipient strain of E. coli using a self-replicating plasmid which also contains a gene, which confers resistance to an antibiotic listed as a critically important antimicrobial. This gene was detected in the food enzyme. The absence of viable cells of the production strain in the food enzyme was not demonstrated. The food enzyme is intended to be used only for the production of a mixture of galacto-oligosaccharides (GOS). Genotoxicity tests did not raise a safety concern. Subchronic toxicity was assessed by means of a repeated dose 90-day oral toxicity study in rats. The Panel identified a no observed adverse effect level at the highest dose tested of 900 mg total organic solids (TOS)/kg body weight (bw) per day. Similarity of the amino acid sequence to those of known allergens was searched and no match was found. The Panel considered that under the intended conditions of use the risk for allergic sensitisation and elicitation reactions by dietary exposure cannot be excluded, but the likelihood is considered low. Given the risk associated with the presence of antibiotic resistance gene in the food enzyme and the lack of data showing the absence of viable cells, the Panel concludes that the use of b-galactosidase produced with the genetically modified E. coli NCIMB 30325 cannot be considered safe.
1.

Introduction
Article 3 of the Regulation (EC) No 1332/2008 1 provides definition for 'food enzyme' and 'food enzyme preparation'.
'Food enzyme' means a product obtained from plants, animals or microorganisms or products thereof including a product obtained by a fermentation process using microorganisms: (i) containing one or more enzymes capable of catalysing a specific biochemical reaction; and (ii) added to food for a technological purpose at any stage of the manufacturing, processing, preparation, treatment, packaging, transport or storage of foods.
'Food enzyme preparation' means a formulation consisting of one or more food enzymes in which substances such as food additives and/or other food ingredients are incorporated to facilitate their storage, sale, standardisation, dilution or dissolution.
Before January 2009, food enzymes other than those used as food additives were not regulated or were regulated as processing aids under the legislation of the Member States. On 20 January 2009, Regulation (EC) No 1332/2008 1 on food enzymes entered into force. This Regulation applies to enzymes that are added to food to perform a technological function in the manufacture, processing, preparation, treatment, packaging, transport or storage of such food, including enzymes used as processing aids. Regulation (EC) No 1331/2008 2 established European Union procedures for the safety assessment and the authorisation procedure of food additives, food enzymes and food flavourings. The use of a food enzyme shall be authorised only if it is demonstrated that:
• it does not pose a safety concern to the health of the consumer at the level of use proposed; • there is a reasonable technological need; and • its use does not mislead the consumer.
All food enzymes currently on the European Union (EU) market and intended to remain on that market as well as all new food enzymes shall be subjected to a safety evaluation by the European Food Safety Authority (EFSA) and an approval via an EU Community list.
The 'Guidance on submission of a dossier on food enzymes for safety evaluation' (EFSA CEF Panel, 2009) lays down the administrative, technical and toxicological data required.
1.1.
Background and Terms of Reference as provided by the requestor
Background as provided by the European Commission
Only food enzymes included in the European Union (EU) Community list may be placed on the market as such and used in foods, in accordance with the specifications and conditions of use provided for in Article 7(2) of Regulation (EC) No 1332/2008 1 on food enzymes.
Five applications have been introduced by the Association of Manufacturers and Formulators of Enzyme Products (AMFEP) for the authorisation of the food enzyme consisting of protease, leucyl amino-peptidase, oryzin and aspergillopepsin I from Aspergillus oryzae and the companiesˋBENEO-Palatinit GmbH 0 for the authorisation of the food enzyme isomaltulose synthase from Protaminobacter rubrum (strain Z12A), 'Nagase (Europa) GmbH' for the authorisation of the food enzyme chitinase from a genetically modified strain Streptomyces violaceoruber (strain pChi), 'Clasado Ingredients Ltd.' for the authorisation of the food enzyme b-galactosidase from a genetically modified strain of Escherichia coli (strain BglA MCB3) and 'Meiji Seika Pharma Co., Ltd.' for the authorisation of the food enzyme consisting aspergillopepsin I and II from Aspergillus niger var. macrosporus (strain DBD-0406).
Following the requirements of Article 12.1 of Regulation (EC) No 234/2011 3 implementing Regulation (EC) No 1331/2008 2 , the Commission has verified that the five applications fall within the scope of the food enzyme Regulation and contain all the elements required under Chapter II of that Regulation.
Terms of Reference
The European Commission requests the European Food Safety Authority to carry out the safety assessments on the food enzymes protease, leucyl amino-peptidase, oryzin and aspergillopepsin I from Aspergillus oryzae, isomaltulose synthase from Protaminobacter rubrum (strain Z12A), chitinase from a genetically modified strain Streptomyces violaceoruber (strain pChi), b-galactosidase from a genetically modified strain of Escherichia coli (strain BglA MCB3) and aspergillopepsin I and II from Aspergillus niger var. macrosporus (strain DBD-0406) in accordance with Article 17.3 of Regulation (EC) No 1332/2008 1 on food enzymes.
Interpretation of the Terms of Reference
The present scientific opinion addresses the European Commission's request to carry out the safety assessment of the food enzyme b-galactosidase from the genetically modified strain of Escherichia coli (E. coli) (strain BglA MCB3).
The applicant indicated a wish to use 'E. coli ' as the formal designation identifying the production strain. 4 However, since this designation is applied to the recipient strain, where it is more appropriate, it cannot be used to unambiguously identify the production strain. As no other clear information is provided in the dossier package (technical dossier or additional information) concerning the name of the production strain, consequently, in this opinion, the deposition number for the production strain (NCIMB 30325) is used throughout to avoid confusion (see assessment).
2.
Data and methodologies
Data
The applicant has submitted a dossier in support of the application for authorisation of the food enzyme b-galactosidase from a genetically modified Escherichia coli strain.
Additional information was requested from the applicant during the assessment process on 22 March 2019 and was subsequently provided (see 'Documentation provided to EFSA'). Following the request for additional data sent by EFSA on 22 March 2019, the applicant requested a clarification teleconference, which was held on 20 May 2019.
Methodologies
The assessment was conducted in line with the principles described in the EFSA 'Guidance on transparency in the scientific aspects of risk assessment' (EFSA, 2009), 'Scientific Opinion on Guidance on the risk assessment of genetically modified microorganisms and their products intended for food and feed use' (EFSA GMO Panel, 2011) and following the relevant existing guidances from the EFSA Scientific Committee.
The current 'Guidance on the submission of a dossier on food enzymes for safety evaluation' (EFSA CEF Panel, 2009) has been followed for the evaluation of the application with the exception of the exposure assessment, which was carried out in accordance with the methodology described in the 'CEF Panel statement on the exposure assessment of food enzymes' (EFSA CEF Panel, 2016).
3.
Assessment 5 The enzyme b-galactosidase typically catalyses the release of terminal non-reducing b-D-galactose residues from b-D-galactosides. The specific enzyme under application also has trans-galactosylation activity. When lactose is used as a substrate, one lactose molecule is hydrolysed to release galactose and glucose while a second lactose molecule acts as recipient for trans-galactosylation resulting in the formation of a trisaccharide. As the concentration of the trisaccharide increases, higher molecular weight galacto-oligosaccharides are produced. The food enzyme b-galactosidase, subject of this assessment, is intended to be used only for the production of a mixture of galacto-oligosaccharides (GOS).
3.1.
Source of the food enzyme 6
The b-galactosidase is produced with a genetically modified bacterium Escherichia coli strain deposited in the UK National Collection of Industrial, Food and Marine Bacteria (NCIMB) under the accession number NCIMB 30325. 7 The identity of the strain was confirmed as E. coli by The parental microorganism is E. coli strain
The recipient strain E. coli contains . 10 11 The applicant indicated a wish to use 'E. coli ' as the formal designation identifying the production strain. 12 However, since this designation is applied to the recipient strain, where it is more appropriate, it cannot be used to unambiguously identify the production strain. As no other clear information is provided in the dossier package concerning the name of the production strain, consequently, in this opinion the deposition number for the production strain (NCIMB 30325 6 ) is used throughout as the unique identifier. The purpose of genetic modification was to enable the production strain to synthesise a bgalactosidase from
Characteristics of the introduced sequences
The recipient strain E. coli 
Safety aspects of the genetic modification
The technical dossier contains all necessary information on the recipient microorganism, the donor organism and the genetic modification process.
The production strain E. coli NCIMB 30325 differs from the recipient strain E. coli by the expression of BbgIV b-galactosidase and the resistance to . 19 The production strain contains confers resistance to , an antibiotic listed as a critically important antimicrobial (WHO, 2018).
Production of the food enzyme 20
The food enzyme is manufactured according to the Food Hygiene Regulation (EC) No 852/2004 21 , with food safety procedures based on hazard analysis and critical control points, and in accordance with current Good Manufacturing Practice (GMP). 22 The production strain is grown as a pure culture using a typical basal industrial medium in a fermentation system with conventional process controls in place.
. 23 After completion of the fermentation cells are physically disrupted to allow the release of the intracellular enzyme. The solid biomass then is removed from the fermentation broth by filtration leaving a supernatant containing the food enzyme. The filtrate containing the enzyme is further purified and concentrated, including in which enzyme protein is retained while most of the low molecular weight material passes the filtration membrane and is discarded. Finally, the food enzyme is prior to analysis. 24 The applicant provided information on the identity of the substances used to control the fermentation as well as in the subsequent downstream processing of the food enzyme.
The Panel considered that sufficient information has been provided on the manufacturing process and the quality assurance system implemented by the applicant.
3.3.
Characteristics of the food enzyme
Properties of the food enzyme
The b-galactosidase is a homodimer of amino acids per subunit. 25 The molecular mass of the mature homodimeric protein, predicted from the DNA sequence analysis, sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and size exclusion chromatography is reported to be kDa. 26 The food enzyme was tested for protease, amylase and lipase (as esterase) activities and no significant levels of these activities were detected. 27 No other enzymatic side activities were reported. 28
The in-house determination of b-galactosidase activity is based on hydrolysis of o-nitrophenyl b-Dgalactopyranoside (reaction conditions: pH 6.8, 40°C, 5 min). The enzymatic activity is determined by measuring the release of o-nitrophenol spectrophotometrically at 420 nm. One Unit of b-galactosidase activity is defined as that amount of enzyme which liberates one micromole of o-nitrophenol per minute under the assay conditions. 29 The food enzyme has a temperature optimum around 55°C (pH 6.5) and a pH optimum around 7.0. Thermostability was tested after a pre-incubation of the food enzyme for 60 min at different temperatures. Under the conditions (pH 6.5) of the applied temperature stability assay, enzyme activity decreased above 55°C showing no residual activity above 60°C. 30
Chemical parameters 31
Data on the chemical parameters of the food enzyme were provided for three commercial food enzyme batches. Batch 2 was used for toxicological tests ( Table 1) .
The average Total Organic Solids (TOS) content of the three food enzyme batches was 90.8%. The average enzyme activity/mg TOS of the three food enzyme batches was 34.2 U/mg TOS.
Purity
The lead content in the three batches was below 1 mg/kg, 32 which complies with the specification for lead (not more than 5 mg/kg) as laid down in the general specifications and considerations for enzymes used in food processing (FAO/WHO, 2006) . In addition, the levels of arsenic, cadmium and mercury 33 were below the limits of detection (LODs) of the employed methodologies. 34 The food enzyme complies with the microbiological criteria as laid down in the general specifications and considerations for enzymes used in food processing (FAO/WHO, 2006), which stipulate that E. coli and Salmonella species are absent in 25 g of sample, and total coliforms do not exceed 30 colony forming units (CFU) per gram. 35 No antimicrobial activity was detected in two batches of the food enzyme. 36 The presence of mycotoxins (total aflatoxin screenaflatoxin B1, B2, G1 and G2 37 ) was examined in three food enzyme batches. All were below the LODs of the applied analytical methods. 34 No information was provided on the possible carry-over of from the fermentation medium into the food enzyme. Any possible genotoxic or systemic toxicity is addressed by the toxicological test provided (see Section 3.4).
An assay made with a commercially available test system for antibiotics was shown not suitable for the detection of in the food enzyme. Although the assay was capable of detecting concentrations greater than 4 ng/mL in buffer, when applied to the food enzyme the detection limit appeared to be in the range of 600 ng/mL or more. 34 The high LOD in the presence of food enzyme can be attributed to the presence of in the food enzyme. Consequently, the presence of is considered unlikely.
Viable cells and DNA of the production strain
Despite being requested, experimental data were not provided to investigate whether viable cells of the production strain were absent in the food enzyme. 12 This was considered insufficient to conclude on the absence of viable cells of the production strain in batches of the food enzyme intended for commercialisation.
A test for recombinant DNA in the food enzyme was made by analysis of two batches of the food enzyme without replication.
(no LOD provided). Experiments using , having a LOD of 0.1 ng spiked DNA/g food enzyme demonstrated the presence in the analysed samples. 38
Toxicological data 39
A battery of toxicological tests including a bacterial gene mutation assay (Ames test), an in vitro micronucleus assay, and repeated dose 14-day and 90-day oral toxicity studies in rats has been provided. The toxicological assays were performed with food enzyme batch 2 ( Table 1) which was considered representative of the food enzyme.
Genotoxicity
Bacterial reverse mutation test
A bacterial reverse mutation assay (Ames test) was performed according to OECD Test Guideline 471 (OECD, 1997a) and following Good Laboratory Practice (GLP) in five strains of Salmonella Typhimurium (TA98, TA100, TA1535, TA1537 and TA102) both in the presence and absence of metabolic activation (S9). 40 The first experiment was carried out using plate incorporation methodology in triplicate using seven different concentrations of the food enzyme (5, 15.81, 50, 158.1, 500, 1,581 and 5,000 lg/plate, corresponding to 4.5, 14.2, 45.0, 142.3, 450.0, 1,422.9 and 4,500 lg TOS/plate). A statistically significant increase in revertant colony numbers was observed in strains TA98 and TA100 in the absence of S9 and in strain TA1535 in the absence and presence of S9 at 5,000 lg/plate (corresponding to 4,500 lg TOS/plate). Increases in the number of bacteria, noted as a thickening of the background bacterial lawn, were observed at 5,000 lg/plate (corresponding to 4,500 lg TOS/plate) in all strains in the absence and presence of S9. These increases were attributed to a histidine feeding effect rather than a mutagenic effect because the test article contains a small amount of histidine (approximately 3.8% or 40 histidine residues).
The second experiment was carried out applying the treat and plate procedure in triplicate using six different concentrations of the food enzyme (156.3, 312.5, 625.0, 1,250, 2,500 and 5,000 lg/mL, corresponding to 140.7, 281.3, 562.5, 1,125, 2,250 and 4,500 lg TOS/mL). No evidence of toxicity was observed. A statistically significant increase in revertant colony numbers was observed in strain TA102 in the presence of S9 at 312.5 lg/mL (corresponding to 281.3 lg TOS/mL). However, this increase (1.2-fold with respect to the control value), observed at a single low concentration, was considered as normal biological variability. In the other strains, the numbers of the revertant colonies were comparable to the values observed in the vehicle control groups, both in the presence and absence of metabolic activation. The Panel concluded that the food enzyme did not induce gene mutations in bacteria under the test conditions of the study.
In vitro micronucleus assay
The in vitro micronucleus assay was carried out according to the OECD Test Guideline 487 (OECD, 2010) and following GLP. 41 Experiments were carried out in duplicates. Cultured human peripheral blood lymphocytes were treated with 375, 750 and 1,500 lg food enzyme/mL (corresponding to 337.5, 675 and 1,350 lg TOS/mL) applying a short-term treatment (3 h followed by 21 h recovery) in the absence of S9, with 3,000, 4,000 and 5,000 lg food enzyme/mL (corresponding to 2,700, 3,600 and 4,500 lg TOS/mL) applying a short-term treatment (3 h followed by 21 h recovery) in the presence of S9, and with 120, 240 and 350 lg food enzyme/mL (corresponding to 108, 216 and 315 lg TOS/mL), applying a continuous treatment (24 + 0 h) in the absence of S9.
Cytotoxicity, detected as a reduction in the replication index (RI) in relation to the vehicle control, reached 57% at the highest concentration tested in long-term experiment without S9 mix. Statistically significant increase in the frequency of micronucleated binucleate (MNBN) cells with respect to the concurrent vehicle control was observed at the lowest concentration analysed (3,000 lg/mL, corresponding to 2,700 lg TOS/mL; giving 16% reduction in RI) for 3 + 21 h treatment in the presence of S-9. However, this isolated observation did not exceed the historical control range and therefore was considered not biologically relevant. The Panel concluded that the food enzyme bgalactosidase did not induce micronuclei in cultured human peripheral blood lymphocytes under the experimental conditions employed for this study.
The Panel concludes on the basis of the in vitro studies there is no concern for genotoxicity for the food enzyme tested.
Repeated dose 14-day oral toxicity study in rodents
A repeated dose 14-day oral toxicity study in rodents was performed to provide the basis for the selection of dose levels for the subsequent 90-day study. 42 The study was not in compliance with GLP.
Groups of three male and three female Wistar HsdHan:WIST strain rats received the food enzyme via gavage at the doses of 10, 100, 300 and 1,000 mg/kg body weight (bw) per day (corresponding to 9, 90, 270 and 900 mg TOS/kg bw per day).
No mortality, clinical signs, effects on body weight, body weight gain or gross pathology were observed. Based on the results from this study, a high dose level of 1,000 mg/kg bw per day (corresponding to 900 mg TOS/kg bw per day) was considered suitable for use in repeated dose 90-day oral toxicity study in rodents.
Repeated dose 90-day oral toxicity study in rodents
A repeated dose 90-day oral toxicity study in rodents was performed according to OECD Test Guideline 408 (OECD, 1998) and following GLP. 43 Groups of 10 male and 10 female Wistar HsdHan: WIST rats received the food enzyme by gavage at doses of 10, 100 and 1,000 mg/kg bw per day (corresponding to 9, 90 and 900 mg TOS/kg bw per day) with a dose volume of 10 mL/kg bw per day. Controls received the vehicle (water for injection).
No mortality was observed. Clinical observation showed that on day 93, a few high-dose males had fur staining. In one highdose female noisy (whisteling) respiration was recorded on day 93 and damage to its left forepaw on days 92 and 93. As these signs were seen in isolation, they were considered to be unrelated to bgalactosidase treatment.
Among haematological parameters, statistically significant differences to controls were observed in treated females only. These differences included a decrease in absolute reticulocytes (high dose), percentage of reticulocytes (mid and high dose), platelet count (all doses), platelet crit (all doses), platelet distribution width (mid and high dose), activated partial thromboplastin time (low dose) and an increase in counts of white blood cells, lymphocytes and monocytes (mid and high dose). All changes were within historical control data ranges from the laboratory, and were considered by the Panel as not toxicologically relevant.
No other significant effects were observed. Overall, the Panel identified a No Observed Adverse Effect Level (NOAEL) of 900 mg TOS/kg bw per day for both males and females, the highest dose tested.
Allergenicity 44
The allergenicity assessment considers only the food enzyme and not any carrier or other excipients which may be used in the final formulation.
The potential allergenicity of the b-galactosidase produced with Escherichia coli NCIMB 30325 was assessed by comparing its amino acid sequence with those of known allergens according to the scientific opinion on the assessment of allergenicity of genetically modified (GM) plants and microorganisms and derived food and feed of the Scientific Panel on Genetically Modified Organisms (EFSA GMO Panel, 2017). Using higher than 35% identity in a window of 80 amino acids as the criterion, no match was found. 45 No oral or respiratory sensitisation or elicitation reactions of this b-galactosidase have been reported, nor have adverse reactions been reported to other b-galactosidases.
Quantifying the risk for allergenicity is not possible in view of the individual susceptibility to food allergens. Allergenicity can be ruled out only if the proteins are fully removed.
The Panel considers that under the intended condition of use the risk of allergic sensitisation and elicitation reactions upon dietary exposure to this food enzyme cannot be excluded but the likelihood of such reactions to occur is considered to be low.
3.5.
Intended use of the food enzyme and dietary exposure
The food enzyme is intended to be used in the production of GOS from lactose at the recommended use level up to 200 mg TOS/kg lactose. 46, 47 Details of the GOS manufacturing process were provided by the applicant. The food enzyme is added to and held to allow the reaction to occur. Afterwards, the reaction mixture is subject to 48 Analytical data provided for one GOS product showed the absence of a b-galactosidase band in the total protein analyses by SDS-PAGE and Coomassie R250 staining. 49 The Panel considered this information insufficient to prove the removal of the food enzyme TOS from the GOS product.
Given the concerns of the Panel on the safety of the food enzyme, dietary exposure was not estimated at this stage.
Conclusions
The presence of recombinant DNA coding for a gene, which confers resistance to an antibiotic listed as a critically important antimicrobial together with the lack of data showing the absence of viable cells in the food enzyme represent a risk. Therefore, the Panel concludes that the use of bgalactosidase produced with the genetically modified E. coli NCIMB 30325 cannot be considered safe.
Documentation provided to EFSA
